## DAY 1-The Race Against Time
### September 13

### 10:30 Welcome and Opening Remarks

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30</td>
<td>The Honorable Michael N. Castle*</td>
</tr>
<tr>
<td></td>
<td>Chair Emeritus, Research!America;</td>
</tr>
<tr>
<td></td>
<td>Governor of Delaware, 1985-1992,</td>
</tr>
<tr>
<td></td>
<td>U.S. Representative, 1993-2011</td>
</tr>
<tr>
<td></td>
<td>Jill Biden, EdD</td>
</tr>
<tr>
<td></td>
<td>First Lady of the United States</td>
</tr>
<tr>
<td></td>
<td>Mary Woolley*</td>
</tr>
<tr>
<td></td>
<td>President and CEO, Research!America</td>
</tr>
</tbody>
</table>

### 10:45 Outsmarting a Global Health Threat: What will it take to keep AMR at bay?

Each year in the United States, more than 2 million people become infected with bacteria that are resistant to antibiotics, and at least 23,000 die as a result of these infections. Globally, an estimated 700,000 deaths per year are attributed to antimicrobial resistance (AMR). The WHO has declared that AMR is one of the top ten global public health threats facing humanity. Combating AMR requires innovation, not just to develop treatments that replace those compromised by AMR, but to slow the trajectory of AMR as much as possible, saving lives and creating space for those new treatments to come to fruition. This interactive roundtable discussion will focus on the latter imperative. What are the strategies that fall under the umbrella of AMR “stewardship?” Can we do more to slow the pace of resistance, and if so, how? How high are the stakes? How is stewardship success measured? What is the outlook absent new strategies and faster development of antimicrobial treatments?

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:45</td>
<td>Alok Patel, MD</td>
</tr>
<tr>
<td></td>
<td>Pediatric Hospitalist, Lucile Packard Children’s Hospital; Special</td>
</tr>
<tr>
<td></td>
<td>Correspondent, ABC News; Pediatric Content Advisor, MedScape; Host, NOVA</td>
</tr>
<tr>
<td></td>
<td>Now Podcast, PBS</td>
</tr>
<tr>
<td></td>
<td>Stefano Bertuzzi, PhD, MPH</td>
</tr>
<tr>
<td></td>
<td>CEO, American Society for Microbiology</td>
</tr>
<tr>
<td></td>
<td>Elizabeth Dodds Ashley, PharmD, MHS, FCCP, BCPS</td>
</tr>
<tr>
<td></td>
<td>Associate Professor of Medicine, Division of Infectious Diseases &amp;</td>
</tr>
<tr>
<td></td>
<td>International Health; Operations Director, DASON, Duke Center for</td>
</tr>
<tr>
<td></td>
<td>Antimicrobial Stewardship and Infection Prevention</td>
</tr>
<tr>
<td></td>
<td>Santiago Gonzalez, MPH</td>
</tr>
<tr>
<td></td>
<td>Senior Policy Advisor, Senator Michael Bennet (D-CO)</td>
</tr>
<tr>
<td></td>
<td>Amanda Jezek</td>
</tr>
<tr>
<td></td>
<td>Senior Vice President, Public Policy and Government Relations,</td>
</tr>
<tr>
<td></td>
<td>Infectious Diseases Society of America</td>
</tr>
<tr>
<td></td>
<td>Rita Livadas, PharmD</td>
</tr>
<tr>
<td></td>
<td>Director of Public Affairs, BD</td>
</tr>
</tbody>
</table>

### 12:00 Living with a Rare Disease: Cystic Fibrosis

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00</td>
<td>Gunner Esiason</td>
</tr>
<tr>
<td></td>
<td>Patient Advocate, Boomer Esiason Foundation</td>
</tr>
</tbody>
</table>

### 12:23 Diagnosing Rare Diseases: A Parent’s Journey

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:23</td>
<td>Christina Hartman</td>
</tr>
<tr>
<td></td>
<td>Vice President of External Affairs, The Assistance Fund</td>
</tr>
</tbody>
</table>
The audience will join renowned leaders in science and technology to take a clear-eyed look at efforts to equip our nation with the S&T capabilities needed to out-innovate existential threats and stay globally competitive. Will current policy efforts to bolster U.S. S&T come to fruition? How do we ensure our nation can continue to successfully compete in the global economy while collaborating internationally to maximize S&T progress? The conversation will fully engage the audience on these critical questions and more.

Sudip Parikh, PhD*
CEO; Executive Publisher, Science Family of Journals, American Association for the Advancement of Science

Mary Woolley*
President and CEO, Research!America

Emil Kakkis, MD, PhD
CEO, President, and Founder UltaGenesis Pharmaceutical Inc.

Michael Ybarra, MD
Vice President of Advocacy and Strategic Alliances and Chief of Medical Affairs, PhRMA

Faster Rare Disease Progress is Within our Reach

Envision360: It Takes an Ecosystem

Mary Woolley*
President and CEO, Research!America

Emil Kakkis, MD, PhD
CEO, President, and Founder UltaGenesis Pharmaceutical Inc.

Michael Ybarra, MD
Vice President of Advocacy and Strategic Alliances and Chief of Medical Affairs, PhRMA

Fireside Chat: The Research Behind Healthcare Excellence

David Meyers, MD
Acting Director, Agency for Healthcare Research and Quality

Lisa Simpson, MB, BCh, MPH, FAAP
President and CEO, AcademyHealth

Sudip Parikh, PhD*
CEO; Executive Publisher, Science Family of Journals, American Association for the Advancement of Science

Lisa Simpson, MB, BCh, MPH, FAAP
President and CEO, AcademyHealth

Fireside Chat: Innovation Amplified: ARPA-H

Haye Husbands Fealing, PhD
Dean, Ivan Allen College of Liberal Arts, Georgia Institute of Technology

Mikael Dolsten, MD, PhD*
Chief Scientific Officer and President, Worldwide Research, Development, and Medical, Pfizer Inc

Marcia McNutt, PhD
President, National Academy of Sciences

Kaye Husbands Fealing, PhD
Dean, Ivan Allen College of Liberal Arts, Georgia Institute of Technology

Sethuraman Panchanathan, PhD
Director, National Science Foundation

Francis Collins, MD, PhD
Director, National Institutes of Health

Eric Lander, PhD
Director, Office of Science and Technology Policy; Science Advisor to the President

Hallie Jackson
Senior Washington Correspondent, NBC News; Host, MSNBC's "Hallie Jackson Reports"

Fireside Chat: Innovation Amplified: ARPA-H

Hallie Jackson
Senior Washington Correspondent, NBC News; Host, MSNBC's "Hallie Jackson Reports"

Sethuraman Panchanathan, PhD
Director, National Science Foundation

Francis Collins, MD, PhD
Director, National Institutes of Health

Eric Lander, PhD
Director, Office of Science and Technology Policy; Science Advisor to the President

* Current or Emeritus Research!America Board Member
Chronic diseases and conditions have figured prominently into the COVID-19 pandemic, increasing the risk associated with and the toll the coronavirus has taken on Americans and populations across the globe. Beyond COVID-19, the human and fiscal costs of this constellation of health threats is staggering: according to the Milken Foundation, the annual economic impact on the U.S. of the seven most common chronic diseases is estimated to be $1.3 trillion, which could grow to approximately $6 trillion by 2050.

This discussion will focus on public and private sector-fueled progress against lupus and Alzheimer’s, two diseases emblematic of the challenges posed by chronic conditions, shedding light on how far we’ve come and how far we have yet to go to defeat them. What are the most promising developments against lupus and Alzheimer’s disease? What is the significance of the regulatory landscape? What role do patients play in determining the direction of progress against these threats?
12:45  
**Fireside Chat: Prevent, Intercept, Eradicate: Reimagining Medical Progress**

**Ellie Dehoney**  
Vice President, Policy and Advocacy, Research!America

**William N. Hait, MD, PhD**  
Global Head, Johnson & Johnson Global External Innovation

---

1:00  
**Writing a Compelling Opinion Piece**

**John Siniff**  
Executive Vice President, Subject Matter; Former Opinion Editor, USA Today

---

2:30  
**Researcher to Researcher: A Fireside Chat with Dr. Anthony Fauci**

**Alexandra Colón-Rodríguez, PhD**  
Postdoctoral Scientist, Neurobiology, Physiology, and Behavior, University of California Davis

**Anthony S. Fauci, MD**  
Director, National Institute of Allergy and Infectious Diseases, NIH

---

2:40  
**Flash Talks Competition**

Featuring young scientists from academia and industry, judged by a panel of science communicators.

**Judges:**

**Dana Acton**  
Director, Science Policy and Legislative Affairs, American Association for Cancer Research (AACR)

**Kafui Dzirasa, MD, PhD**  
K. Ranga Rama Krishnan Endowed Associate Professor of Psychiatry and Behavioral Sciences, Duke University Medical Center

**Joel Beetsch, PhD**  
Vice President of Corporate Affairs, Eisai, Inc.

**Lauren Powell, MPA, PhD**  
President & CEO, The Equitist, LLC; Vice President, US Health Equity & Community Wellness, Takeda Pharmaceuticals

**Andrea Morgan**  
Graduate Research Assistant, Behavioral and Systems Neuroscience Program, Oregon Health & Science University

**Andrew Quinn, PhD**  
Neurology Research Fellow, Alzheimer's Clinical & Translational Research Unit (ACTRU), Massachusetts General Hospital and Harvard Medical School

**Faiza Siddqui, PhD**  
Research Associate, Department of Internal Medicine, University of South Florida

---

*Current or Emeritus Research!America Board Member*
DAY 3—Defining the Path Forward
September 15

10:45
The Challenge and Imperative of Advancing Diversity in Cancer Clinical Trials

Jeff Allen, PhD
President and CEO, Friends of Cancer Research

Peter C. Adamson, MD
Global Head, Oncology Development and Pediatric Innovation, Sanofi

11:00
Can We Truly Conquer Cancer?

The participants in this discussion will explore the path to progress against cancer from several different vantage points. Bringing together representatives from the patient community, the federal government, academia, and industry, the discussion will highlight the roles the public and private sector play in cancer-focused discovery, development, and delivery; hone in on the extraordinary potential inherent in breakthroughs such as immunology and CRISPR, and what those leaps in progress mean for the spectrum of cancer threats; shed light on the challenges that have rendered progress elusive against some forms of the disease such as glioblastoma and pancreatic cancer; and look at ways the horizon may be shifting (e.g., the possibility of new platforms that enable progress against multiple forms of cancer at once; the role of new clinical trial designs) as the fight to overcome cancer continues.

Jeff Allen, PhD
President and CEO, Friends of Cancer Research

Ned Sharpless, MD
Director, National Cancer Institute, NIH

Julia Beaver, MD
Chief of Medical Oncology, Oncology Center of Excellence; Deputy Director (Acting), Office of Oncologic Diseases, Center for Drug Evaluation and Research, FDA

John Carpten, PhD
Professor and Chair, Department of Translational Genomics; Director, Institute for Translational Genomics, Keck School of Medicine, University of Southern California

Jacqueline Corrigan-Curay, JD, MD
Principal Deputy Center Director, Center for Drug Evaluation and Research, FDA

Lisa Lacasse
President, American Cancer Society Cancer Action Network

David Reese, MD
Executive Vice President, Research and Development, Amgen

* Current or Emeritus Research!America Board Member
12:30  **Diversity, Equity, & Inclusion: Tracking Progress and Measuring Success**

The roundtable participants — with audience input and a focus on the health-focused R&D workforce and workplace — will share strategies for advancing and evaluating diversity, equity, and inclusion (DEI). What are the best practices for advancing workforce and workplace DEI? Are there approaches that appeared to hold promise, but have proven ineffective? Are current definitions of DEI too broad or too narrow to promote the wellbeing of individuals across the R&D workforce? What quantitative and qualitative measures accurately capture DEI progress? What are the key attributes of a diverse, equitable and inclusive workforce and workplace?

- **Jessica Bylander**  
  Senior Editor and Correspondent, Health Affairs

- **Thomas LaVeist, PhD**  
  Dean and Weatherhead Presidential Chair in Health Equity, Tulane University School of Public Health and Tropical Medicine

- **Chetana Rao, PhD**  
  Head, Site Strategy & Operations, Redwood City, San Francisco, Bristol Myers Squibb

- **Robert Sellers, PhD**  
  Vice Provost for Equity & Inclusion and Chief Diversity Officer; Charles D. Moody Collegiate Professor of Psychology, University of Michigan

- **Esther C. Nolton, PhD, MEd**  
  Program Officer, Evaluation and Analysis, Patient-Centered Outcomes Research Institute

- **Keith Yamamoto, PhD**  
  Vice Chancellor for Science Policy and Strategy; Director, UCSF Precision Medicine; Professor, Cellular & Molecular Pharmacology, University of California, San Francisco

1:30  **ENVISION 360: Defining Success in Clinical Trial Diversity**

- **Rachael Fones**  
  Director, Government & Public Affairs, IQVIA

1:45  **A View from the Problem Solvers Caucus**

- **Jenny Luray**  
  Vice President of Strategy and Communications, Research!America

- **The Honorable Josh Gottheimer**  
  U.S. Representative (D-NJ-05)

- **The Honorable Charlie Dent**  
  Executive Director & Vice President, The Aspen Institute; Senior Policy Advisor, DLA Piper LLP; U.S. Representative, 2005-2018

2:00  **COVID-19 Vaccines: A Conversation with FDA’s Peter Marks**

- **Amy Comstock Rick, JD**  
  President and CEO, Food and Drug Law Institute

- **Peter Marks, MD, PhD**  
  Director, Center for Biologics Evaluation & Research, FDA

2:20  **Envision360: Global Threats Cross Borders: Dengue Fever**

- **Derek Wallace, MBBS**  
  Vice President and Global Dengue Program Head, Vaccine Business Unit, Takeda Pharmaceuticals

2:26  **Fireside Chat: Preparedness Can and Must Move Faster**

- **Janette Nesheiwat, MD**  
  Medical Director at CityMD, Fox News Medical Contributor

- **Tom Frieden, MD, MPH**  
  President and CEO, Resolve to Save Lives, an initiative of Vital Strategies; Former Director, CDC

3:00  **ENVISION360: Championing Self-Care**

- **Laurie Hernandez**  
  Olympic Gymnastics Champion and One Mind Ambassador

*Current or Emeritus Research!America Board Member*
What’s important in health care? Medical and public health progress that bring about safe and effective solutions; affordability for individual patients and for our healthcare system as a whole; access to the benefits of medical progress; and health equity, which depends on progress, affordability, and access, are certainly cornerstones of an effective health care system. Looking at prescription drugs as one piece of the health care puzzle, this interactive roundtable discussion will explore the challenges, imperatives, and options for simultaneously advancing progress, affordability, access, and equity.

Mark McClellan, MD, PhD*
Director, Robert J. Margolis Center for Health Policy, Duke University; Former Administrator, CMS, 2004-2006; Former Commissioner, FDA, 2002-2004

Peter Pronovost, MD, PhD
Chief Quality & Clinical Transformation Officer, University Hospitals; Professor, Department of Anesthesiology and Critical Care Medicine, School of Medicine and School of Nursing, Case Western Reserve University

Gary Puckrein, PhD
President and CEO, National Minority Quality Forum

Mark Reisenauer
President, Astellas Pharma US

Cynthia Zagieboylo*
President and CEO, National MS Society

* Current or Emeritus Research!America Board Member

THANK YOU TO OUR SPONSORS!

LEAD SPONSOR

Pfizer

FORUM PARTNER SPONSORS

HORIZON SANOFI

ROUNDTABLE SPONSORS

AdvaMed

AMGEN

BD

Bristol Myers Squibb

AMERICAN SOCIETY FOR MICROBIOLOGY

REGENERON

SCIENCE TO MEDICINE™

GlaxoSmithKline

Lilly

cori.

Envision360

SPECIAL SPEAKER SERIES SPONSORS

Alnylam

Colgate

Eisai

Johnson & Johnson

DAILY HOST

SPECIAL SPEAKER SERIES SPONSORS

ultragenyx

VERTEX

RITA ALLEN FOUNDATION

Envision360

WORKSHOP SPONSOR

ACRO

PARMA

Takeda

Updated as of 9/10/21
The Research!America alliance advocates for science, discovery, and innovation to achieve better health for all.